The humanitarian medical organisation Medecins Sans Frontieres (MSF) has called on Johnson & Johnson to cut the price of its anti-tuberculosis medicine Sirturo (bedaquiline), to not mor
The FDA has approved Novartis’s new eye drug brolucizumab for wet age-related macular degeneration, which will match Bayer’s rival Eylea on price per dose but reduce costs with a less frequ
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
